Oncogenomics: prospects for the future.

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00

abstract：:Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

journal_title：Expert review of anticancer therapy

authors： Onesti CE,Jerusalem G

更新日期：2020-12-13 00:00:00

abstract：INTRODUCTION:Angiogenesis is critical for tumor growth, proliferation and metastasis with the crucial role of Vascular Endothelial Growth factor (VEGF) pathway. Ramucirumab is a monoclonal antibody that specifically targets the extracellular domain of Vascular Endothelial Growth Factor Receptor 2. Areas covered: We per...

journal_title：Expert review of anticancer therapy

authors： Paulus V,Avrillon V,Pérol M

更新日期：2016-11-01 00:00:00

abstract：:As with many human malignancies, pancreatic cancer is a complex genetic disorder. Several thousand disease-associated alterations on the DNA, mRNA, miRNA and protein levels have been reported to date. Some of these alterations, including a number of gatekeeper mutations, which are of pre-eminent importance for the ons...

journal_title：Expert review of anticancer therapy

authors： Buchholz M,Gress TM

更新日期：2009-10-01 00:00:00

abstract：:Ductal carcinoma-in situ (DCIS) is a non-obligate precursor for invasive breast cancer and concern exists regarding the potential for overdiagnosis and overtreatment as the natural history of DCIS progression to invasive breast cancer may never occur or take decades in some cases. Preoperative systemic therapy window ...

journal_title：Expert review of anticancer therapy

authors： Kuerer HM

更新日期：2015-01-01 00:00:00

abstract：:Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air o...

journal_title：Expert review of anticancer therapy

authors： Taivans I,Bukovskis M,Strazda G,Jurka N

更新日期：2013-12-13 00:00:00

abstract：:Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...

journal_title：Expert review of anticancer therapy

authors： Cuttino LW,Vicini FA

更新日期：2011-09-01 00:00:00

abstract：:Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer...

journal_title：Expert review of anticancer therapy

authors： Planchard D

更新日期：2011-08-01 00:00:00

abstract：INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

journal_title：Expert review of anticancer therapy

authors： Greenwell IB,Flowers CR,Blum KA,Cohen JB

更新日期：2017-03-01 00:00:00

abstract：:Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

journal_title：Expert review of anticancer therapy

authors： Taplin ME

更新日期：2008-09-01 00:00:00

abstract：:We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% C...

journal_title：Expert review of anticancer therapy

authors： Li Y,Fu XH,Yuan JQ,Yang ZY,Mao C,Dong XM,Tang JL,Wang SY

更新日期：2015-06-01 00:00:00

abstract：:For over 40 years, fluorouracil has been the only drug registered for the treatment of metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens including either irinotecan or oxaliplatin have proven to be superior to fluorouracil monotherapy in randomized clinical trials, in terms of re...

journal_title：Expert review of anticancer therapy

authors： Pessino A,Sobrero A

更新日期：2006-05-01 00:00:00

abstract：:Anemia in cancer patients is frequent but often under-recognized and under-treated. This may be related to misconceptions about the impact of anemia on cancer patients and ill-defined guidelines for treatment, as well as the inadequacies of current therapy. Darbepoetin alfa, a novel erythropoiesis-stimulating protein ...

journal_title：Expert review of anticancer therapy

authors： Pirker R,Smith R

更新日期：2002-08-01 00:00:00

abstract：:Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

journal_title：Expert review of anticancer therapy

authors： Roussos Torres ET,Epstein AL

更新日期：2021-01-19 00:00:00

abstract：:Bacillus Calmette-Guérin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have...

journal_title：Expert review of anticancer therapy

authors： Wang Y,Yang M,Yu Q,Yu L,Shao S,Wang X

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Bednarikova M,Cibula D,Zikan M

更新日期：2016-12-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：:The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and melanoma progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signaling can inhibit multiple cellular processes involved in melanoma progression and me...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Grazzini M,Gandini S,Benemei S,Asbury CD,Marchionni N,Geppetti P

更新日期：2012-11-01 00:00:00

abstract：:Neurocognitive function (NCF) impairment is an important component of primary and metastatic brain tumors and their therapeutic interventions. As a result, modern clinical trials of cranial irradiation for adult cancer patients have incorporated NCF testing as a primary or secondary end point. In doing so, these clini...

journal_title：Expert review of anticancer therapy

authors： Caine C,Mehta MP,Laack NN,Gondi V

更新日期：2012-05-01 00:00:00

abstract：:Introduction: Management of clinically negative neck (cN0) in patients with parotid gland cancer is controversial. Treatment options can include observation, elective neck dissection or elective radiotherapy. Areas covered: We addressed the treatment options for cN0 patients with parotid gland cancer. A literature rev...

journal_title：Expert review of anticancer therapy

authors： Vartanian JG,Gonçalves Filho J,Kowalski LP,Shah JP,Suárez C,Rinaldo A,De Bree R,Rodrigo JP,Hamoir M,Takes RP,Mäkitie AA,Zbären P,Andreasen S,Poorten VV,Sanabria A,Hellquist H,Robbins KT,Bödeker CC,Silver C,Ferlito A

更新日期：2019-10-01 00:00:00

abstract：:Increased cancer risk after renal transplantation is believed to be a consequence of continuous immunosuppression. However, the risk of colorectal cancer (CRC) after renal transplantation is controversial and has received limited study. Accumulating evidence suggests that colon and rectal cancers have different charac...

journal_title：Expert review of anticancer therapy

authors： Kan M,Gill JS,Wiseman SM

更新日期：2008-08-01 00:00:00

abstract：:Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:In the recent years, melanoma patients' outcome and survival improved, mainly because of systemic treatment improvement with targeted therapy and checkpoint blockade. Targeted therapy with BRAF and MEK inhibitors was approved to treat patients with unresectable or metastatic melanoma, harboring BRAF V600 m...

journal_title：Expert review of anticancer therapy

authors： Amaral T,Nouri N,Garbe C

更新日期：2016-07-01 00:00:00

abstract：:Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor bio...

journal_title：Expert review of anticancer therapy

authors： Graner MW,Bigner DD

更新日期：2006-05-01 00:00:00

abstract：:Renal neoplasms exhibit a wide spectrum of molecular characteristics that are closely associated with their diverse morphologic manifestations and clinical behaviors. A wealth of information has been garnered via methodology ranging from classical cytogenetics to FISH and gene expression profiling; however, the exact ...

journal_title：Expert review of anticancer therapy

authors： Cheng L,Williamson SR,Zhang S,Maclennan GT,Montironi R,Lopez-Beltran A

更新日期：2010-06-01 00:00:00

abstract：:Bladder cancer is rare in patients below the age of 50 years, and most patients are in their 60s and 70s. Radical cystectomy is the preferred approach for patients with localized disease in most European countries and the USA, and evidence is growing in favor of neoadjuvant, platinum-based chemotherapy for patients at...

journal_title：Expert review of anticancer therapy

authors： Basso U,Bassi P,Sava T,Monfardini S

更新日期：2004-12-01 00:00:00

abstract：:Colorectal cancer (CRC) is the third most common malignancy and cause of death from cancer among adults worldwide. In recent years, the use of 5-fluorouracil-based regimens in combination with molecularly targeted agents has greatly expanded treatment options for patients with metastatic disease. With a more capillary...

journal_title：Expert review of anticancer therapy

authors： Ribecco AS,Pino MS,Cipriani G,Marinozzi C,Fioretto L

更新日期：2013-10-01 00:00:00

abstract：:Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

journal_title：Expert review of anticancer therapy

authors： Gordon MS

更新日期：2011-03-01 00:00:00

abstract：:The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage. Preoperative chemotherapy results in downstaging in a significant percentage...

journal_title：Expert review of anticancer therapy

authors： Bamias A,Dimopoulos MA

更新日期：2005-12-01 00:00:00